Literature DB >> 31727757

Are Linear Measurements of the Nucleus Basalis of Meynert Suitable as a Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer Disease?

K D Jethwa1, P Dhillon2, D Meng2, D P Auer2.   

Abstract

BACKGROUND AND
PURPOSE: Cell loss within the nucleus basalis of Meynert is an early event in Alzheimer disease. The thickness of the nucleus basalis of Meynert (NBM) can be measured on structural MR imaging. We investigated NBM thickness in relation to cognitive state and biochemical markers.
MATERIALS AND METHODS: Mean bilateral nucleus basalis of Meynert thickness was measured on coronal T1-weighted MR imaging scans from the Alzheimer's Disease Neuroimaging Initiative dataset. Three hundred and fifteen scans (80 controls, 79 cases of early mild cognitive impairment, 77 cases of late mild cognitive impairment and 79 cases of Alzheimer disease) were assessed. Alzheimer's Disease Assessment Scale-Cognitive scores, CSF tau, and amyloid quantification were extracted. Group differences in NBM thickness, their correlates and measurement reliability were assessed.
RESULTS: Mean NBM thickness ± SD progressively declined from 2.9 ± 0.3, 2.5 ± 0.3, and 2.3 ± 0.3 to 1.8 ± 0.4 mm in healthy controls, patients with early mild cognitive impairment, late mild cognitive impairment and Alzheimer disease respectively (P < .001). NBM thickness was negatively correlated with Alzheimer's Disease Assessment Scale-Cognitive scores (r = -0.53, P < .001) and weakly positively correlated with CSF amyloid (r = 0.250, P < .001) respectively. No association with CSF tau was found. NBM thickness showed excellent diagnostic accuracy to differentiate Alzheimer disease (area under the curve, 0.986) and late mild cognitive impairment from controls (area under the curve, 0.936) with excellent sensitivity, but lower specificity 66.7%. Intra- and interrater reliability for measurements was 0.66 and 0.47 (P < .001).
CONCLUSIONS: There is progressive NBM thinning across the aging-dementia spectrum, which correlates with cognitive decline and CSF markers of amyloid-β pathology. We show high diagnostic accuracy but limited reliability, representing an area for future improvement. NBM thickness is a promising, readily available MR imaging biomarker of Alzheimer disease warranting diagnostic-accuracy testing in clinical practice.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31727757      PMCID: PMC6975347          DOI: 10.3174/ajnr.A6313

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

Review 1.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

2.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

3.  Atrophy of the cholinergic Basal forebrain over the adult age range and in early stages of Alzheimer's disease.

Authors:  Michel Grothe; Helmut Heinsen; Stefan J Teipel
Journal:  Biol Psychiatry       Date:  2011-08-04       Impact factor: 13.382

4.  Phase enhanced PSIR T1 weighted imaging improves contrast resolution of the nucleus basalis of Meynert at 7 T: a preliminary study.

Authors:  Ketan Jethwa; Kingkarn Aphiwatthanasumet; Olivier Mougin; Richard Bowtell; Dorothee Auer; Penny Gowland
Journal:  Magn Reson Imaging       Date:  2019-06-13       Impact factor: 2.546

5.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

6.  Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects.

Authors:  Michel J Grothe; Michael Ewers; Bernd Krause; Helmut Heinsen; Stefan J Teipel
Journal:  Alzheimers Dement       Date:  2014-01-10       Impact factor: 21.566

7.  MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices.

Authors:  R Insausti; K Juottonen; H Soininen; A M Insausti; K Partanen; P Vainio; M P Laakso; A Pitkänen
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

8.  Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior.

Authors:  D V Cicchetti; S A Sparrow
Journal:  Am J Ment Defic       Date:  1981-09

9.  Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis.

Authors:  J Berger-Sweeney; S Heckers; M M Mesulam; R G Wiley; D A Lappi; M Sharma
Journal:  J Neurosci       Date:  1994-07       Impact factor: 6.167

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  3 in total

1.  New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders.

Authors:  Chesney E Craig; Nicola J Ray; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Curr Behav Neurosci Rep       Date:  2020-10-09

2.  Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis.

Authors:  Franziska E Hildesheim; Ralph H B Benedict; Robert Zivadinov; Michael G Dwyer; Tom Fuchs; Dejan Jakimovski; Bianca Weinstock-Guttman; Niels Bergsland
Journal:  J Neurol       Date:  2021-05-16       Impact factor: 4.849

3.  Anticholinergic drugs and forebrain magnetic resonance imaging changes in cognitively normal people and those with mild cognitive impairment.

Authors:  Dewen Meng; Ali-Reza Mohammadi-Nejad; Stamatios N Sotiropoulos; Dorothee P Auer
Journal:  Eur J Neurol       Date:  2022-02-07       Impact factor: 6.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.